Cosmo Pharmaceuticals N.V.

SWX:COPN 주식 보고서

시가총액: CHF 1.1b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cosmo Pharmaceuticals 미래 성장

Future 기준 확인 4/6

Cosmo Pharmaceuticals (는) 각각 연간 18.7% 및 10.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 14.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.2% 로 예상됩니다.

주요 정보

19.3%

수익 성장률

16.4%

EPS 성장률

Pharmaceuticals 수익 성장11.5%
매출 성장률12.3%
향후 자기자본 수익률15.0%
애널리스트 커버리지

Low

마지막 업데이트24 Jul 2024

최근 미래 성장 업데이트

Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recent updates

Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

May 02
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

May 20
Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

Apr 03
Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Mar 07
When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

What Kind Of Investors Own Most Of Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Feb 01
What Kind Of Investors Own Most Of Cosmo Pharmaceuticals N.V. (VTX:COPN)?

수익 및 매출 성장 예측

SWX:COPN - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026219771121083
12/31/202522079991054
12/31/20242491131151024
12/31/202393-51834N/A
9/30/20239932135N/A
6/30/2023104112436N/A
3/31/2023103142535N/A
12/31/2022102172633N/A
9/30/202290261724N/A
6/30/20227835816N/A
3/31/20227228614N/A
12/31/20216522413N/A
9/30/2021646816N/A
6/30/202163-111219N/A
3/31/202162-9816N/A
12/31/202061-8513N/A
9/30/202064-7-16N/A
6/30/202067-7-80N/A
3/31/202065-16-22-9N/A
12/31/201962-24-36-19N/A
9/30/201956-28-35-17N/A
6/30/201950-31-34-15N/A
3/31/201958-24-27-12N/A
12/31/201866-18-20-10N/A
9/30/201869-20-23-10N/A
6/30/201873-23-26-11N/A
3/31/201870-28-29-10N/A
12/31/201768-32-31-9N/A
9/30/201768-18N/A-6N/A
6/30/201769-4N/A-2N/A
3/31/2017698N/A10N/A
12/31/20166819N/A22N/A
9/30/20167018N/A18N/A
6/30/20167216N/A14N/A
3/31/201666132N/A-13N/A
12/31/201561248N/A-39N/A
9/30/201560241N/A-13N/A
6/30/201559234N/A13N/A
3/31/201569154N/A40N/A
12/31/20148073N/A66N/A
9/30/20147678N/A43N/A
6/30/20147282N/A20N/A
3/31/20146575N/A14N/A
12/31/20135769N/A8N/A
9/30/20135166N/A7N/A

애널리스트 미래 성장 예측

수입 대 저축률: COPN 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 0.2% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: COPN (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: COPN 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: COPN 의 수익(연간 10.7% ) Swiss 시장( 4.4% 보다 빠르게 성장할 것으로 예상됩니다. 4.4% 연간).

고성장 수익: COPN 의 수익(연간 10.7% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: COPN 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 14.2 %).


성장 기업 발견